A detailed history of Hexagon Capital Partners LLC transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Hexagon Capital Partners LLC holds 9,533 shares of GILD stock, worth $853,298. This represents 0.16% of its overall portfolio holdings.

Number of Shares
9,533
Previous 10,217 6.69%
Holding current value
$853,298
Previous $700,000 14.14%
% of portfolio
0.16%
Previous 0.15%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 08, 2024

SELL
$66.59 - $83.99 $45,547 - $57,449
-684 Reduced 6.69%
9,533 $799,000
Q2 2024

Jul 12, 2024

BUY
$63.15 - $72.88 $95,103 - $109,757
1,506 Added 17.29%
10,217 $700,000
Q1 2024

Apr 18, 2024

SELL
$71.58 - $87.29 $53,398 - $65,118
-746 Reduced 7.89%
8,711 $638,000
Q4 2023

Feb 05, 2024

SELL
$73.27 - $83.09 $12,822 - $14,540
-175 Reduced 1.82%
9,457 $766,000
Q3 2023

Oct 23, 2023

BUY
$73.94 - $80.67 $90,058 - $98,256
1,218 Added 14.48%
9,632 $721,000
Q2 2023

Jul 24, 2023

SELL
$76.01 - $86.7 $30,632 - $34,940
-403 Reduced 4.57%
8,414 $648,000
Q1 2023

Apr 24, 2023

BUY
$77.31 - $88.08 $618 - $704
8 Added 0.09%
8,817 $731,000
Q4 2022

Jan 13, 2023

SELL
$62.32 - $89.47 $164,275 - $235,842
-2,636 Reduced 23.03%
8,809 $0
Q3 2022

Oct 17, 2022

BUY
$59.54 - $68.01 $364,325 - $416,153
6,119 Added 114.89%
11,445 $706,000
Q2 2022

Jul 21, 2022

BUY
$57.72 - $65.01 $97,489 - $109,801
1,689 Added 46.44%
5,326 $329,000
Q1 2022

Apr 13, 2022

BUY
$57.92 - $72.58 $87,922 - $110,176
1,518 Added 71.64%
3,637 $216,000
Q2 2021

Aug 11, 2021

BUY
$63.47 - $69.35 $12,694 - $13,869
200 Added 10.42%
2,119 $146,000
Q1 2021

May 13, 2021

BUY
$60.0 - $68.46 $30,000 - $34,230
500 Added 35.24%
1,919 $124,000
Q4 2020

Feb 05, 2021

SELL
$56.65 - $64.55 $16,995 - $19,365
-300 Reduced 17.45%
1,419 $82,000
Q3 2020

Nov 10, 2020

BUY
$62.1 - $78.08 $106,749 - $134,219
1,719 New
1,719 $100,000

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $112B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Hexagon Capital Partners LLC Portfolio

Follow Hexagon Capital Partners LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hexagon Capital Partners LLC, based on Form 13F filings with the SEC.

News

Stay updated on Hexagon Capital Partners LLC with notifications on news.